Targeting ANXA2 also showed potential value in terms of anti-tumor therapy; the monoclonal antibody ch2448, which targets ANXA2, was reported to kill breast and ovarian cancer cells in vivo as well as in vitro via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-drug conjugate (ADC) routes [60]. The gene discussed is ANXA2; the disease is ovarian carcinoma.